Results 191 to 200 of about 118,257 (252)

Tracking the evolution of multiple in vitro HCV replicon mutants under protease inhibitor selection pressure by 454 ultra deep sequencing. [PDF]

Claes, Marijke, Fanning, G, Lenz, O, Neyts, Johan, Simmen, K, Van Marck, H, Vandenbroucke, I, Verbinnen, T, Vijgen, L   +8 more
core  

Antiviral Inflammasomes and How to Find Them. [PDF]

Viruses
Wuerth JD, Schmidt FI.
europepmc   +1 more source

Phenotypic impacts of treatment-selected mutations in HIV-2 protease on darunavir and lopinavir susceptibility: Evaluating genotypic HIV-2 drug resistance tools. [PDF]

PLOS Glob Public Health
Raugi DN, Nixon RS, Smith RA, Hawes SE, Diallo K, Diallo MB, Faye K, Diaw B, Sy MP, Sall F, Seydi M, Gottlieb GS, University of Washington-Senegal HIV-2 Study Group.   +12 more
europepmc   +1 more source

Designing Potent HIV‑1 Protease Inhibitors Using Machine Learning and QSAR Approaches. [PDF]

ACS Omega
Ali S, Dwi Putra I, Chuntakaruk H, Wolschann P, Maitarad P, Rungrotmongkol T, Hannongbua S.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

HIV protease inhibitors

AIDS, 1996
The protease encoded by the human immunodeficiency virus (HIV protease) mediates the maturation of newly formed HIV particles through proteolytic processing of the gag and gag-pol gene products. Because of its essential role in the HIV replication cycle, this enzyme represents a logical target for the treatment of HIV infection.
A, Carr, D A, Cooper
  +7 more sources

HIV-Protease Inhibitors

New England Journal of Medicine, 1998
Inhibitors of human immunodeficiency virus (HIV)–encoded protease, combined with nucleoside analogues with antiretroviral activity, cause profound and sustained suppression of viral replication, reduce morbidity, and prolong life in patients with HIV infection.1–3 Recent guidelines recommend that initial treatment of all HIV-infected patients include ...
G. Di Perri, P. Del Bravo, CONCIA, Ercole   +2 more
  +6 more sources

Heterocyclic HIV-Protease Inhibitors

Current Medicinal Chemistry, 2013
In the panorama of HIV protease inhibitors (HIV PIs), many efforts have been devoted to the development of new compounds with reduced peptidic nature in order to improve pharmacokinetics and pharmacodynamics features. The introduction of cyclic scaffolds in the design of new chemical entities reduces flexibility and affords more rigid inhibitors ...
CALUGI, CHIARA, GUARNA, ANTONIO, TRABOCCHI, ANDREA   +2 more
openaire   +3 more sources